Curriculum vitae for mark cushman - Purdue College of Pharmacy ...

41
Mark Cushman
41. "Design, Synthesis, and Biological Evaluation of Cosalane, a Novel Anti-HIV Agent
which Inhibits Multiple Features of Virus Replication", Cytel Corporation, San Diego,
California, July 10, 1995.
42. "Design, Synthesis, and Biological Evaluation of Cosalane, a Novel Anti-HIV Agent
which Inhibits Multiple Features of Virus Replication", University of Missouri - Kansas
City, August 17, 1995.
43. "Basic Science Research at Purdue University", Indiana University HIV/AIDS Research
Consortium, Indiana State Department of Health, Indianapolis, Indiana, April 17, 1996.
44. " Synthesis and Biological Evaluation of Certain Alkenyldiarylmethanes (ADAMs) as
Anti-HIV Agents which Act as Non-Nucleoside Reverse Transcriptase Inhibitors,"
University of Missouri - Kansas City, September 26, 1996.
45. "Recent Advances in the Chemotherapy of AIDS", West Lafayette Sagamore Lyons
Club, West Lafayette, Indiana, April 28, 1997.
46. "I. Synthesis of Inhibitors of Tubulin Polymerization. II. Synthesis of Inhibitors of
Lumazine Synthase and Riboflavin Synthase," Lehrstühl für Organische Chemie und
Biochemie der Technischen Universität München, August 6, 1997, Munich, Germany.
47. "I. Synthesis of Inhibitors of Tubulin Polymerization. II. Synthesis of Inhibitors of
Lumazine Synthase and Riboflavin Synthase," University of Missouri - Kansas City,
September 26, 1997.
48. "Synthesis of ADAMs and Cosalane Analogs with Enhanced Potencies as Anti-HIV
Agents," Cytel Corporation, San Diego, California, March 26, 1998.
49. "Design and Synthesis of Novel Anti-HIV Agents: Inhibitors of Viral Attachment and
Reverse Transcription," Department of Chemistry, Ohio Northern University, Ada, Ohio.
April 2, 1998.
50. "Design and Synthesis of Potential Anticancer Agents which Target Tubulin
Polymerization, Topoisomerase I, and Protein Trafficking," Developmental Therapeutics
Program, National Institutes of Health, Rockville, Maryland, August 14, 1998.
51. "Design and Synthesis of Potential Anticancer Agents which Target Tubulin
Polymerization and Topoisomerase I," EntreMed, Inc., Rockville, Maryland, December
9, 1998.
52. "Investigation of the Binding of Fluorolumazines to the 1-MDa Capsid of Lumazine
Synthase by
15 N{ 19 F} REDOR NMR, " University of Minnesota, Minneapolis,
Minnesota, April 13, 1999.
53. "Bioseparations Engineering of Natural Products," Purdue Chromatography Workshop,
Purdue University, West Lafayette, Indiana, October 11, 1999.
54. "Ligands for Probing the Active Site of Lumazine Synthase," Indiana University
Northeast, Gary, Indiana, March 1, 2000.
55. "Metabolically Stable Analogs of Hypothetical Intermediates in the Reactions Catalyzed
by Lumazine Synthase and Riboflavin Synthase," 32 nd American Chemical Society
Regional Meeting, Covington, Kentucky, May 18, 2000.
56. "Design, Synthesis, and Biological Evaluation of New Cosalanes," Tularik, Inc., South
San Francisco, September 8, 2000.
57. "Design, Synthesis, and Biological Evaluation of New Anti-HIV Agents which Inhibit
gp120-CD4 Binding and RANTES-Induced Chemotaxis," Munich Technical University,
Garching, Germany, September 22, 2000.
58. "Metabolically Stable Analogs of Hypothetical Intermediates in the Reactions Catalyzed
by Lumazine Synthase and Riboflavin Synthase," 3-Dimensional Pharmaceuticals, Inc.,
Exton, Pennsylvania, June 8, 2001.